01-04-2007: Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically-directed library compounds to Amgen's discovery programs. Under the terms of the extended agreement, Galapagos will receive an upfront fee of $2.4 million as a payment for 2007 research costs. Additionally, Galapagos may receive compensation in the form of library and technology access fees, research fees, milestone payments, and bonuses.
The initial collaboration, announced in January 2003, involves the identification of lead candidates against multiple ion channel targets. The new agreement expands this collaboration to include all classes of targets, including ion channel, GPCR and kinase targets. Additionally, the agreement has been expanded to include the supply of BioFocus DPI's compound collection comprising 700,000 synthetic small molecules and its proprietary natural product compound collection containing 145,000 pre-purified subfractions, pure natural products, and semi-synthetic natural products.
Predictive genetic test for bowel cancer treatment is introduced in the UK
Amgen Limited UK and Lab21 have announced their partnership to introduce a new genetic therapy test for advanced bowel cancer treatment in the UK. Under the terms of the agreement, Lab21 will provide a screening test to indicate which patients are likely to benefit from Amgen's new drug for ... more
Graffinity and Amgen enter into drug discovery research agreement
Graffinity Pharmaceuticals GmbH announced that it has entered into a research collaboration with Amgen. Under the terms of the agreement, Graffinity will receive technology access fees and success payments for the generation of novel small molecule hits against a broad range of drug targets ... more
Galapagos expands and extends drug discovery collaboration with Amgen into 2008
Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically- ... more
Galapagos wins 2011 Scrip Award for Biotech Company of the Year
Galapagos NV announced that it won the prestigious Scrip Award for Biotech Company of the Year at last night's ceremony in London. The award recognizes the biotech company that has achieved the most in the 12-month period from June 2010 to May 2011.The international jury, which consisted o ... more
Galapagos expands and extends drug discovery collaboration with Amgen into 2008
Galapagos NV announced that its service division BioFocus DPI has expanded and extended its longstanding drug discovery collaboration with Amgen through 2007 and 2008. BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply biologically- ... more
Galapagos and The ALS Association announce EUR2.4 million target discovery alliance
Galapagos NV and The ALS Association, a non-profit health organization dedicated to finding a cure for amyotrophic lateral sclerosis (ALS), announced a new two-year target discovery alliance. Galapagos' service division BioFocus DPI will apply its adenoviral platform to identify drug target ... more
About analytica-world.com
analytica-world.com is the industry portal of the international trade fair analytica, which is organized by Messe München. It features useful information about markets, trends and innovations. It is operated by CHEMIE.DE, one of analytica's official sales partners.
Advertising at analytica-world.com
Our advertising formats support you in getting your message across to a clearly defined target audience.
The global network of analytica trade fairs:
